Starpharma Holdings Ltd Asset Resilience Ratio

Latest as of December 2025: 69.74%

Starpharma Holdings Ltd asset resilience ratio. Starpharma Holdings Ltd (SPL) has an Asset Resilience Ratio of 69.74% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See SPL defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Liquid Assets

AU$18.25 Million
≈ $12.91 Million USD Cash + Short-term Investments

Total Assets

AU$26.17 Million
≈ $18.51 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio of Starpharma Holdings Ltd (2016–2025)

Asset resilience ratio of Starpharma Holdings Ltd from 2016 to 2025. This chart shows how Starpharma Holdings Ltd's Asset Resilience Ratio has changed over time. Read Starpharma Holdings Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Starpharma Holdings Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Starpharma Holdings Ltd assets under control.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$18.25 Million 69.74%
Short-term Investments AU$0.00 0%
Total Liquid Assets AU$18.25 Million 69.74%

Asset Resilience Insights

  • Very High Liquidity: Starpharma Holdings Ltd maintains exceptional liquid asset reserves at 69.74% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Starpharma Holdings Ltd Industry Peers by Asset Resilience Ratio

Compare Starpharma Holdings Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Samsung Biologics Co Ltd
KO:207940
Biotechnology 15.21%
Abivax SA
PA:ABVX
Biotechnology 2.58%
Tubize-Fin
BR:TUB
Biotechnology 2.50%
BB Biotech AG
SW:BION
Biotechnology 92.97%
Sinocelltech Group Ltd
SHG:688520
Biotechnology 5.27%
Inner Mongolia Furui Med Sci
SHE:300049
Biotechnology 1.75%
Mineralys Therapeutics, Inc. Common Stock
NASDAQ:MLYS
Biotechnology 78.33%
GH Research PLC
NASDAQ:GHRS
Biotechnology 4.73%

Starpharma Holdings Ltd Asset Resilience Ratio by Year (2016–2025)

Starpharma Holdings Ltd asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for Starpharma Holdings Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-06-30 59.40% AU$15.10 Million
≈ $10.68 Million
AU$25.42 Million
≈ $17.99 Million
-2.61pp
2024-06-30 62.01% AU$22.83 Million
≈ $16.15 Million
AU$36.81 Million
≈ $26.05 Million
-2.34pp
2023-06-30 64.35% AU$33.52 Million
≈ $23.72 Million
AU$52.09 Million
≈ $36.85 Million
-4.85pp
2022-06-30 69.20% AU$45.79 Million
≈ $32.40 Million
AU$66.17 Million
≈ $46.82 Million
-9.04pp
2021-06-30 78.24% AU$57.30 Million
≈ $40.54 Million
AU$73.24 Million
≈ $51.82 Million
+11.74pp
2020-06-30 66.49% AU$25.98 Million
≈ $18.39 Million
AU$39.08 Million
≈ $27.65 Million
-11.91pp
2019-06-30 78.40% AU$38.31 Million
≈ $27.10 Million
AU$48.86 Million
≈ $34.57 Million
-3.58pp
2018-06-30 81.98% AU$47.97 Million
≈ $33.94 Million
AU$58.51 Million
≈ $41.40 Million
-4.88pp
2017-06-30 86.85% AU$57.84 Million
≈ $40.92 Million
AU$66.59 Million
≈ $47.12 Million
--
2016-06-30 0.00% AU$0.00
≈ $0.00
AU$59.04 Million
≈ $41.77 Million
--
pp = percentage points

About Starpharma Holdings Ltd

AU:SPL Australia Biotechnology
Market Cap
$155.27 Million
AU$219.45 Million AUD
Market Cap Rank
#17307 Global
#505 in Australia
Share Price
AU$0.46
Change (1 day)
+1.10%
52-Week Range
AU$0.32 - AU$0.87
All Time High
AU$2.49
About

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRA… Read more